Know Cancer

forgot password

A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer

Phase 2
18 Years
Not Enrolling
Esophageal Neoplasms

Thank you

Trial Information

A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer

Inclusion Criteria:

- Patients must have a histologically or cytologically proven metastatic or recurrent
esophageal cancer. Both adenocarcinoma and squamous carcinoma are eligible for the
study. Patients with small cell carcinoma or sarcoma of the esophagus are not
eligible for the study.

- Patients may have had no prior chemotherapy treatment for metastatic esophageal
cancer. Patients may have had chemotherapy with 5-FU combined with definitive
radiotherapy for curative intent in the adjuvant, neoadjuvant, or definite setting
for locally advanced esophageal cancer, if no less than one year prior to trial
enrollment. Patients may not have received pemetrexed in the past.

- Patients who have had radiotherapy for esophageal cancer must have completed
radiotherapy at least four weeks prior to entry in the study.

- Patients need to have measurable disease.

- Lesions that are not considered measurable include the following:

- Bone lesions

- Brain metastases or leptomeningeal disease

- Ascites

- Pleural/pericardial effusion

- Abdominal masses that are not confirmed and followed by imaging techniques

- Cystic lesions

- Tumor lesions situated in a previously irradiated area

- ECOG) performance status of 0-2.

- Life expectancy of >12 weeks.

- Patients must have adequate bone marrow function defined as: white blood cells (WBC)
>= 3000/mm3, absolute neutrophil count (ANC) >= 1,500/mm3, hemoglobin >= 9.0 g/dL,
and platelet count >= 100,000/mm3.

- Patients must have adequate liver function defined as: Bilirubin <= 1.5 x
institutional normal and ALT/AST < 3 x institutional normal.

- Patients must have adequate renal function defined as: serum creatinine <= 3.0 mg/dL
and creatinine clearance >= 45 mL/min.

- Radiation therapy for brain metastases should be completed at least four weeks prior
to enrollment to this protocol.

- Patients must have recovered from uncontrolled intercurrent illness including, but
not limited to, ongoing or active infection, symptomatic congestive heart failure,
unstable angina pectoris, or uncontrolled symptomatic cardiac arrhythmia.

- Patients must be able to be compliant with premedications of dexamethasone, folic
acid, and vitamin B12.

- For all sexually active women of child-bearing age, the use of adequate contraception
(hormonal or barrier method of birth control) will be required prior to study entry
and for the duration of study participation.

- Age >= 18 years.

- Written consent.

- Ibuprofen (400 mg qid) can be administered with Alimta in patients with normal
renal function (creatinine clearance > 80 mL/min

Exclusion Criteria:

- Patients with third-space fluid (pleural effusions, ascites, etc.) uncontrolled by

- Pregnant or nursing females

- Patients who have had pre-existing neuropathy greater than or equal to grade 2.

- Patients with known active CNS metastases.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine response rates in patients with esophageal cancer when treated with pemetrexed and carboplatin

Outcome Description:

Every 2 cycles during treatment. If complete response, partial response or stable disease every 2 months for 1st 6 months following end of treatment, then every 3 months for the next year, and then every 6 months thereafter.

Outcome Time Frame:

Throughout treatment and follow-up

Safety Issue:


Principal Investigator

Maria Q. Baggstrom, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Washington University School of Medicine


United States: Institutional Review Board

Study ID:

06-0541 / 201103198



Start Date:

October 2006

Completion Date:

June 2010

Related Keywords:

  • Esophageal Neoplasms
  • Neoplasms
  • Esophageal Diseases
  • Esophageal Neoplasms



Washington University School of MedicineSaint Louis, Missouri  63110